Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Equity Average: 2009-2021

Historic Equity Average for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to $120.3 million.

  • Avadel Pharmaceuticals' Equity Average fell 107.24% to -$7.9 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$7.9 million, marking a year-over-year decrease of 107.24%. This contributed to the annual value of $120.3 million for FY2021, which is 80.74% up from last year.
  • Avadel Pharmaceuticals' Equity Average amounted to $120.3 million in FY2021, which was up 80.74% from $66.5 million recorded in FY2020.
  • Avadel Pharmaceuticals' 5-year Equity Average high stood at $120.3 million for FY2021, and its period low was -$13.2 million during FY2019.
  • For the 3-year period, Avadel Pharmaceuticals' Equity Average averaged around $57.9 million, with its median value being $66.5 million (2020).
  • In the last 5 years, Avadel Pharmaceuticals' Equity Average plummeted by 129.90% in 2019 and then skyrocketed by 603.68% in 2020.
  • Avadel Pharmaceuticals' Equity Average (Yearly) stood at $63.8 million in 2017, then tumbled by 30.78% to $44.2 million in 2018, then crashed by 129.90% to -$13.2 million in 2019, then spiked by 603.68% to $66.5 million in 2020, then spiked by 80.74% to $120.3 million in 2021.